Al-Najjar, one of the three hospitals in Rafah, is no longer functioning due to the ongoing hostilities in the vicinity and the military operation in Rafah
Merck & Co Inc and partner Ridgeback Biotherapeutics said on Friday six lab studies showed their experimental oral Covid-19 drug molnupiravir was active against the fast-spreading Omicron variant.
The data evaluated the antiviral activity of molnupiravir and other Covid-19 antiviral agents against Covid-19 variants of concern. Molnupiravir is yet to be studied against Omicron in human studies, the companies said.
Molnupiravir and a rival oral pill from Pfizer Inc were authorised in the United States in December and are considered as important tools against Omicron.
Pfizer said in December lab data suggested its drug Paxlovid retained its effectiveness against Omicron.
Merck said earlier this month its pill has a mechanism that can work against Omicron and any other variant.
Molnupiravir has been authorised for use in more than 10 countries, including the United States, United Kingdom and Japan.
ALSO READ:
Al-Najjar, one of the three hospitals in Rafah, is no longer functioning due to the ongoing hostilities in the vicinity and the military operation in Rafah
The tweet also informed people of the different details that a single ID card can provide
Airport expected to increase its capacity to 25 million passengers annually by 2027
Core taxi segment revenue up 15% year-on-year
The precious metal has climbed approximately 12% this year
Since last month, many residents have resorted to expensive alternatives like taxis, while others endure significantly longer travel times
In authorised school buses, drivers and nannies are trained to conduct thorough checks of the bus before locking and leaving it
Bitcoin’s scarcity remains a key driver of its value, attracting long-term investors